The survival rate of patients with hepatocellular carcinoma and extrahepatic metastases is very poor. Sorafenib, a targeted chemotherapy agent, has been shown effective for patients with advanced hepatocellular carcinoma (HCC), but it is associated with serious side effects. In addition, although surgery has been regarded as effective for lung metastases from HCC, its use in these patients is limited. Complementary and alternative medicine, including traditional Korean medicine (TKM), is increasingly used in cancer treatment, as it has been found to improve patient quality of life and maintain tumor size. This report describes a 62-year-old Korean woman with lung metastases from HCC. She first underwent surgery (stage IV) and six cycles of adjuvant chemotherapy. She was subsequently treated with sorafenib, but computed tomography showed progressive disease and she experienced the side effects of sorafenib. The patient started treatment with TKM, including pharmacopuncture and herbal medicine, in addition to sorafenib. After 8 weeks of TKM treatment, the size of the metastatic nodules decreased and the sorafenib-associated side effect symptoms improved. These findings suggest that treatment with a combination of TKM and sorafenib may be a promising method for patients with HCC and extrahepatic metastases.
INTRODUCTION
Primary liver cancer is a major cause of cancer deaths worldwide. 1 The incidence of liver cancer is especially high in Eastern Asia. 2 Most primary liver cancers are hepatocellular carcinomas (HCCs), which have a poor prognosis, due to their high recurrence and metastasis rates. 3 About 34.5 % of patients with HCC experience pulmonary metastases, as HCCs most frequently metastasize to the lungs. 4À5 The prognosis of these patients is be very poor, with, for example, the 1-year survival rate of HCC patients with extrahepatic metastasis being only 21.7À24.9%. 6 Sorafenib, an oral multikinase inhibitor with antiproliferative and antiangiogenic properties, 7 has recently been approved to treat patients with advanced HCC and good liver functions. However, sorafenib has various side effects, including diarrhea, handÀfoot skin reaction (HFS), rash, and fatigue. 8 Although surgery has been regarded as effective in resecting lung metastasis from HCC, 9 surgery has limitations in these patients. 1 These limitations of conventional treatments indicates a need to develop novel treatments for patients with advanced HCC.
Complementary and alternative medicine (CAM), including traditional Korean medicine (TKM), is increasingly used in cancer treatment. 10 Recent studies have reported that 95% of cancer patients use CAM.
11À12 CAM can improve patient quality of life and maintain tumor size. This report describes a patient with HCC and lung metastases who experienced relief of symptoms induced by chemotherapy and shrinkage of the lung lesions following administration of sorafenib and TKM.
PATIENT AND METHODS

Patient characteristics and medical history
A 62-year-old Korean woman was diagnosed with metastatic lung cancer from HCC in November 2014. She underwent left hemihepatectomy and video-assisted thoracic surgery (VATS), which included left lower lobe (LLL) wedge resection and embolectomy of the inferior vena cava. After surgery, her cancer was identified as stage IV. She received six cycles of chemotherapy with adriamycin and cisplatin. She was subsequently administered 800 mg/day sorafenib, but, after 2 weeks, experienced side effects, including skin rash, HFS, and thrombocytopenia. Following the easing of these side effects, she was restarted on 400 mg/day sorafenib. Chest computed tomography (CT) in December 2015 showed stable disease (SD). Chest CT in February 2016 revealed progressive disease (PD), including increases in the sizes of metastatic nodules in both lungs, despite continuing on sorafenib. Therefore, in April 2016, this patient visited our hospital to receive TKM, along with sorafenib. At that time, she was classified as having Eastern Cooperative Oncology Group (ECOG) performance status 1 and had sorafenib-induced side effect such as diarrhea and numbness of the feet.
Treatment course
Beginning in 2016, the patient was treated with both TKM and sorafenib. The TKM treatments, which consisted of pharmacopuncture with wild ginseng (WG), Cordyceps militaris (CM), and Prunella vulgaris var. lilacina NAKAI (PV); nasal fumigation; herbal medicine; moxibustion; and herbal medicated foot bath, were administered twice a week. The WG pharmacopuncture (WGP) solution was prepared by heating 200 g of cultivated wild ginseng, cleaned thoroughly in running water firstly in 2 L distilled water for about 2 h. After removing the residue, the bath solution was transferred to a distillation extractor in a clean room. This solution was filtered twice with 0.45 mm and 0.2 mm filters, and 8 mL were injected into a sterilized 10 cc container. The sterilized sample was sealed again, and the WGP sample was injected intravenously. The CM pharmacopuncture (CMP) solution was prepared by heating 450 g Cordyceps militaris, washed thoroughly in running water, in 9 L distilled water for 3 h. After removing the residue, 6 L of the bath liquid was placed in a distillation extractor in a clean room. The resulting solution was filtered twice with 0.45 mm and 0.2 mm filters, and 8 mL were injected into a sterilized 10 cc container. The sterilized sample was sealed again, and the CMP sample was administered intravenously. The PV pharmacopuncture (PVP) solution was prepared by dissolving 18 g of bamboo salt in 1 L of distilled water, with a salinity of 1.8 confirmed with a salinity meter. Separately, 2 g of freeze-dried powder of Prunella vulgaris var. was dissolved in 1 L of sterilized distilled water. The two solutions were mixed, and the salinity was adjusted to 0.9. The resulting solution was filtered twice with 0.45 mm and 0.2 mm filters, and 4 mL were injected into a sterilized 6 cc container. The solution for nasal fumigation consisted of a 1:1 mixture of the wild ginseng and CM pharmacopuncture solutions described above. A 16 mL aliquot of the mixture was injected into a sterilized 20 cc container and again sterilized. Moxibustion was applied to acupoints in the abdomen (CV 4, CV 8, and ST 25) for 20 min to stimulate these acupoints with heat energy and to promote qi. The patient was also orally administered 7.98 g/day bulhwangeum junggi-san (Kyoungbang, Korea) for 39 days to treat diarrhea. The patient was also given three 20 min foot baths per day for 7 days, each consisting of two bags of 6.18 g Bojungikki-tang (Hanpoong, Korea), dissolved completely in 2 L of lukewarm water.
RESULTS
Chest CT in June 2016 showed a reduction in size of the metastatic nodules in both lungs, compared with chest CT in February 2016. The size of the tumor in the left upper lobe lingula had decreased from 22 mm to 13 mm ( Fig. 1(a) ), as did the other tumor in the left upper lobe lingula, from 15 mm to 14 mm (Fig. 1(b) ). The size of the metastatic nodule in the right lower lobe also decreased, from 18 mm to 8 mm (Fig. 2) . The serum concentration of the tumor marker CA 19-9 decreased from 40.1 U/L to 34.7 U/L after 2 months of treatment. The serum concentration of AST and LDH also decreased, but were higher than the upper limit of the normal range. The serum concentrations of ALT, ALP, total bilirubin, BUN, and Cr were within their normal ranges, with TKM treatment having no significant adverse effects. In addition, diarrhea and foot numbness improved after herbal medicine treatment. DISCUSSION HCC is highly resistant to cytotoxic chemotherapy agents, with response rates of only about 20% and no improvements in patient survival period. Sorafenib is a multi-targeted inhibitor of tyrosine kinases, including B-Raf, vascular endothelial growth factor receptor (VEGFR), and platelet derived growth factor receptor (PDGFR). Sorafenib can therefore block tumor progression by inhibiting tumor angiogenesis. The side effects of sorafenib include HFS, hypertension, heart ischemia, and diarrhea. 13 A phase III randomized, double-blind, placebo-controlled trial on 602 patients with HCC and Child-Pugh A liver function found that only 2.3% of sorafenib-treated patients showed a partial response (PR), with 71% having stable disease (SD). 8 A second phase III trial of patients in the Asia-Pacific region found that the PR and 
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EXPLORE September/October 2018, Vol. 14, No. 5 Combined Treatment for Lung Metastasis from Hepatocellular Carcinoma SD rates in sorafenib-treated patients were 3.3% and 54%, respectively. 7 The patient in this case study was diagnosed with HCC and lung metastasis in November 2014. She underwent left hemihepatectomy and LLL wedge resection, followed by six cycles of chemotherapy with adriamycin and cisplatin. She started sorafenib treatment in November 2015, but experienced side effects, including diarrhea and HFS. In February 2016, after taking sorafenib for 3 months, the size of her tumor increased on CT. She therefore started TKM treatments at our hospital in April 2016, while still taking sorafenib. Her sorafenib-associated side effects, including diarrhea and HFS, almost completely disappeared. A CT scan 2 months later, in June 2016, showed a reduction in size of her lung metastases.
The major TKM treatment of this patient was WGP. Many studies have evaluated the effects on ginsenosides, the principal components of ginseng, on acute and chronic liver diseases, including liver cancer. For example, treatment of human HCC cells with various doses of ginsenoside Rh2 (GRh2) resulted in a dose-dependent reduction in the viability of HCC cells and of cells similar to cancer stem cells (CSCs). In addition, GRh2 increased autophagy and inhibited b-catenin signaling related to HCC, pancreatic cancer, and colon cancer.
14 Ginsenoside Rg3 (GRg3), another principal component of ginseng, has also been shown to significantly inhibit the proliferation of HCC cell lines, including MMC-7721, Hep1-6, and HepG2, and to promote their apoptosis.
15À16
Drug interactions between ginseng extract (GE) and sorafenib were determined by measuring the level of phosphorylation of extracellular signal-regulated kinase (pERK) in four human cancer cell lines in vitro and in vivo. That study found that ginseng extract and sorafenib interacted with each other, and that their combinational use of GE and sorafenib could GE-dose-dependently affected the sensitivity of tumor cells for sorafenib by potentiating an antitumor response to this agent. 17 A study of ginseng and cancer therapy in Egyptian patients with chronic liver diseases found that this combination significant improved liver function in patients infected with hepatitis C virus (HCV), as well as reducing tumor marker levels and viral titers. 18 Moreover, a mini-review reported that ginseng/ginsenoside had a wide array of pharmacological activities in regulating liver functions and the treatment of liver disorders. 19 Taken together, these findings provide further evidence for the therapeutic effects of ginseng against HCV and liver cancer.
The patient in this case study was treated with a combination of wild ginseng and sorafenib. WG may have directly reduced HCC viability and tumor progression. Alternatively, WG may have potentiated the antitumor effects of sorafenib. However, we could not control or measure WG concentrations or determine the effects of WG the other TKM treatments.
In conclusion, we found that the combination of sorafenib and WG pharmacopuncture, including other TKM treatments, for just 2 months significantly reduced tumor size, as well as the side effects of sorafenib. These findings provide further evidence for the efficacy of WG and other TKM treatments in patients with HCC.
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